Various clinical trials have demonstrated the efficacy of TDF-FTC in the prevention of HIV infection. In 2010 Grant et al published the first study in Pre-exposure prophylaxis completed in humans. The Pre-exposure prophylaxis initiative (IPrEx) trial, a multinational randomized, double blinded placebo controlled trial to evaluate safety and efficacy of Truvada compared with placebo for prevention of HIV infection. The participants were followed for 3324 person years and the efficacy of TDF-FTC was reported at 44% (13).
A PrEP trial among African women by Lut Van Damme et al in 2012. They enrolled healthy HIV negative individuals, 18 to 35 years of age and at an increased risk of HIV infection in a randomized, double blinded placebo controlled trial. Incident rate was 4.7 per 100 person years in the TDF-FTC group and 5.0 per 100 person years for the placebo group. Another randomized placebo controlled trial by Morazzo et al in African women to assess daily treatment with TDF-FTC as PrEP against HIV infection showed an incidence of HIV infection of 5.7 per 100 person years. Incidence was highest among women